These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8090782)

  • 1. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
    Kohl NE; Wilson FR; Mosser SD; Giuliani E; deSolms SJ; Conner MW; Anthony NJ; Holtz WJ; Gomez RP; Lee TJ
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9141-5. PubMed ID: 8090782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of ras farnesyl protein transferase inhibitors. Tetrapeptide analogs with amino methyl and carbon linkages.
    Wai JS; Bamberger DL; Fisher TE; Graham SL; Smith RL; Gibbs JB; Mosser SD; Oliff AI; Pompliano DL; Rands E
    Bioorg Med Chem; 1994 Sep; 2(9):939-47. PubMed ID: 7712129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
    Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
    Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
    Prendergast GC; Davide JP; deSolms SJ; Giuliani EA; Graham SL; Gibbs JB; Oliff A; Kohl NE
    Mol Cell Biol; 1994 Jun; 14(6):4193-202. PubMed ID: 8196657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K; Nagasu T
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
    James G; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
    Lebowitz PF; Davide JP; Prendergast GC
    Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.
    Tahir SK; Gu WZ; Zhang HC; Leal J; Lee JY; Kovar P; Saeed B; Cherian SP; Devine E; Cohen J; Warner R; Wang YC; Stout D; Arendsen DL; Rosenberg S; Ng SC
    Eur J Cancer; 2000 Jun; 36(9):1161-70. PubMed ID: 10854950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
    Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
    Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
    Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB; Kohl NE; Koblan KS; Omer CA; Sepp-Lorenzino L; Rosen N; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A
    Breast Cancer Res Treat; 1996; 38(1):75-83. PubMed ID: 8825125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.
    Lebowitz PF; Sakamuro D; Prendergast GC
    Cancer Res; 1997 Feb; 57(4):708-13. PubMed ID: 9044849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.